S-1/A: Panbela Therapeutics Seeks $20 Million in Public Offering Amid Nasdaq Delisting Concerns

Panbela Therapeutics launches a best efforts public offering of common stock and warrants to raise capital and address Nasdaq compliance issues.

Summary

• Panbela Therapeutics is conducting a best efforts public offering of up to 3,007,519 shares of common stock, along with Class E and Class F warrants to purchase additional shares.
• The assumed combined public offering price is $6.65 per share and accompanying warrants, based on the last sale price on January 18, 2024.
• The offering also includes pre-funded warrants for certain purchasers who would otherwise exceed beneficial ownership limits.
• The company intends to use the net proceeds for the continued clinical development of its product candidates ivospemin and eflornithine, as well as for working capital and general corporate purposes.
• Panbela is facing potential delisting from the Nasdaq Capital Market due to non-compliance with minimum bid price and stockholders' equity requirements.
• A 1-for-20 reverse stock split was implemented on January 18, 2024, to address the minimum bid price requirement.
• The company is appealing the Nasdaq staff determination letter and is awaiting a hearing panel decision.
• The offering is scheduled to terminate on February 15, 2024, but may be completed sooner or terminated at the company's discretion.
• Roth Capital Partners, LLC is acting as the exclusive placement agent for the offering.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company is actively pursuing clinical development and has achieved some regulatory milestones, the financial challenges and Nasdaq delisting concerns weigh heavily on the outlook.

Positives

• The company has ongoing clinical trials for its lead drug candidates, ivospemin and Flynpovi.
• Ivospemin has received Fast Track status and orphan drug designation for pancreatic cancer in the United States and Europe.
• The company has regained North American rights to develop and commercialize Flynpovi in patients with FAP.
• The company has a research agreement with Johns Hopkins School of Medicine.
• The company has a sponsored research agreement with The University of Texas MD Anderson Cancer Center.
• US WorldMeds received FDA approval for Eflornithine (DFMO) in Pediatric Neuroblastoma, first polyamine approval in oncology.

Negatives

• The company is facing potential delisting from the Nasdaq Capital Market.
• The company has a history of negative operating cash flow and has an accumulated deficit.
• The company's auditors have expressed substantial doubt regarding its ability to continue as a going concern.
• The company is dependent on third parties for the manufacture of and formulation of our product candidates means that we are subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control.

Risks

• The company's ability to obtain additional capital is uncertain.
• The company's lack of diversification increases the risk of an investment.
• Clinical trials are expensive and time-consuming, and their outcome is highly uncertain.
• The company relies on third parties to conduct clinical trials and for the production of product candidates.
• The markets for the company's product candidates are highly competitive and are subject to rapid scientific change.
• The company may be exposed to infringement or misappropriation claims by third parties.
• The company may be required to defend lawsuits or pay damages for product liability claims.
• The company may be subject to claims that its employees have wrongfully used or disclosed alleged trade secrets of their former employers.
• Federal and state pharmaceutical marketing compliance and reporting requirements may expose the company to regulatory and legal action by state governments or other government authorities.
• If any of the product candidates the company develops become subject to unfavorable pricing regulations, third party reimbursement practices or healthcare reform initiatives, the company's ability to successfully commercialize its product candidates may be impaired.

Future Outlook

The company intends to continue the clinical development of its product candidates ivospemin and eflornithine and for working capital, and other general corporate purposes, which may include repayment of debt.

Industry Context

The announcement reflects the challenges faced by small-cap biopharmaceutical companies in securing funding and maintaining regulatory compliance in a competitive and capital-intensive industry. The company's focus on orphan drug designations and fast track status aligns with industry strategies to expedite drug development and commercialization.

Comparison to Industry Standards

• The company's approach to drug development, focusing on polyamine metabolism, is similar to that of other companies targeting specific metabolic pathways in cancer.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biopharmaceutical industry, particularly for smaller companies.
• The company's pursuit of orphan drug designation and fast track status is consistent with industry efforts to expedite the development and approval of drugs for rare diseases and unmet medical needs.
• The company's decision to implement a reverse stock split to regain compliance with Nasdaq listing requirements is a common strategy employed by companies facing delisting.

Stakeholder Impact

• Shareholders face potential dilution from the public offering.
• Shareholders face potential loss of investment if the company is delisted from Nasdaq.
• Employees' job security is dependent on the company's ability to secure funding and continue operations.
• Patients may benefit from the continued development of new cancer treatments.
• Creditors face increased risk of non-payment if the company's financial situation deteriorates.

Next Steps

• Complete the public offering.
• Continue clinical development of ivospemin and eflornithine.
• Appeal Nasdaq staff determination letter.
• Seek stockholder approval for Class D warrants.
• Monitor and address Nasdaq compliance requirements.

Key Dates

Keywords

Panbela Therapeutics, public offering, common stock, warrants, ivospemin, eflornithine, Flynpovi, Nasdaq, delisting, clinical trials, reverse stock split, biopharmaceutical, cancer, FAP, CPP